Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Gynecologic 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 2Stomach Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × tasquinimod × Clear all
NCT01743469 2019-01-08

A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers

Ipsen

Phase 2 Completed
201 enrolled 23 charts
GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Liver Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms

NCT00560482 2015-10-26

Efficacy Study of ABR-215050 to Treat Prostate Cancer

Active Biotech AB

Phase 2 Completed
206 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT01234311 2015-10-21

A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Active Biotech AB

Phase 3 Completed
1,245 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡